Skip to search formSkip to main contentSkip to account menu

Microprolactinoma

Known as: Microprolactinomas 
A pituitary prolactin cell adenoma of less than 10 mm diameter. [HPO:probinson]
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Prolactinoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature.
Microprolactinomas are the most common pituitary adenomas. In symptomatic patients, dopamine agonists are the first-line… 
Review
2007
Review
2007
Etiological diagnosis of hyperprolactinemia.
Review
2007
Review
2007
Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy.
Highly Cited
2003
Highly Cited
2003
Clinical presentation and outcome of pituitary adenomas in teenagers
objective Pituitary adenomas rarely occur in childhood and adolescence, but their mass effect and endocrine abnormalities can… 
Highly Cited
2000
Highly Cited
2000
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas
To compare effectiveness and tolerability of quinagolide (CV 205–502) and cabergoline (CAB) treatments in 39 patients with… 
Review
1999
Review
1999
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological… 
Highly Cited
1998
Highly Cited
1998
Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease
The ability of MRI to detect pituitary ACTH‐secreting adenomas in patients with Cushing's disease is limited. Owing to different… 
Highly Cited
1997
Highly Cited
1997
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in tumoral hyperprolactinemia… 
Highly Cited
1991
Highly Cited
1991
Megavoltage pituitary irradiation in the management of prolactinomas: long‐term follow‐up
objective To determine the long‐term effects of external beam megavoltage radiotherapy (RT: 4500 cGy via three portals at 180 cGy… 
Highly Cited
1983
Highly Cited
1983
Natural history of microprolactinomas: six-year follow-up.
A 6-year follow-up of patients harboring microprolactinomas suggests that few patients (3 of 27) demonstrate significant growth… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)